Conexeu Completes 12-Month Preclinical Study for Tissue Restoration Platform.
Conexeu Sciences Inc. completed a 12-month study validating the CXU platform for tissue restoration and suitable injectability. This milestone supports the company’s strategy to enter the medical aesthetics market, capitalizing on the growing demand for tissue restoration driven
View filing at SEC.gov →